Genetics of Recurrent Early Onset Major Depression
7 other identifiers
observational
2,302
1 country
6
Brief Summary
This study will identify specific genes that may cause a predisposition to depression in some families.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2005
Typical duration for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2005
CompletedFirst Submitted
Initial submission to the registry
November 28, 2005
CompletedFirst Posted
Study publicly available on registry
December 1, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2009
CompletedApril 19, 2019
April 1, 2019
3.7 years
November 28, 2005
April 16, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Major depressive disorder diagnosis
The study will correlate genome-wide SNP genotypes with case vs. control status, defined by presence or absence of major depressive disorder. Participants will attend an interview regarding personal and family history of psychiatric disorders, and give a blood specimen. Genotypes from blood samples will be studied for association with presence of major depressive disorder.
One patient interview session (typically 2 hours), and blood draw (10-20 minutes)
Eligibility Criteria
The study will include participants with a family history of depression.
You may qualify if:
- History of recurrent major depression
- Has a parent or sibling with a history of recurrent major depression
- Depression began before the age of 31
You may not qualify if:
- Bipolar I (manic-depressive) disorder
- Schizophrenia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Stanford Universitylead
- National Institute of Mental Health (NIMH)collaborator
Study Sites (6)
Stanford University
Palo Alto, California, 94304, United States
Howard University
Washington D.C., District of Columbia, 20060, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
University of Iowa
Iowa City, Iowa, 52242, United States
Johns Hopkins University
Baltimore, Maryland, 21287, United States
Columbia University/New York State Psychiatric Institute
New York, New York, 10032, United States
Related Links
Biospecimen
Blood samples with DNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Douglas F. Levinson, MD
Stanford University
- PRINCIPAL INVESTIGATOR
Myrna M. Weissman, PhD
Columbia University/New York State Psychiatric Institute
- PRINCIPAL INVESTIGATOR
J. Raymond DePaulo, MD
Johns Hopkins University
- PRINCIPAL INVESTIGATOR
William A. Scheftner, MD
Rush University Medical Center
- PRINCIPAL INVESTIGATOR
William Coryell, MD
University of Iowa
- PRINCIPAL INVESTIGATOR
William Lawson, MD
Howard University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle Investigator
Study Record Dates
First Submitted
November 28, 2005
First Posted
December 1, 2005
Study Start
October 1, 2005
Primary Completion
June 1, 2009
Study Completion
June 1, 2009
Last Updated
April 19, 2019
Record last verified: 2019-04